N
AMLX icon

Numerai’s Amylyx Pharmaceuticals AMLX Stock Holding History

Numerai’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515K Sell
28,665
-19,888
-41% -$308K 0.04% 564
2026
Q1 		$675K Sell
48,553
-64,095
-57% -$902K 0.07% 448
2025
Q4 		$1.36M Buy
112,648
+45,495
+68% +$618K 0.16% 195
2025
Q3 		$913K Buy
+67,153
New +$632K 0.13% 218

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Numerai's AMLX Position: Q2 2026 in Review

Numerai reduced its Amylyx Pharmaceuticals (AMLX) stake by 41% in Q2 2026, selling an estimated $308K and leaving 28,665 shares worth $515K. The position accounts for 0.04% of the portfolio, ranked #564.

Numerai first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.36M in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Numerai held 28,665 shares of Amylyx Pharmaceuticals worth $515K as of Q2 2026.
  • Numerai sold 19,888 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $308K.
  • Amylyx Pharmaceuticals made up 0.04% of Numerai's portfolio in Q2 2026, its #564 holding.
  • Numerai first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Numerai's Amylyx Pharmaceuticals position peaked at $1.36M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Numerai's 13F filing for Q2 2026, filed 14 Aug 2026.